To evaluate the efficacy and safety of gildeuretinol in reducing atrophic lesion growth in patients with Stargardt disease.
Key Findings:
Gildeuretinol reduces toxic vitamin A dimerization by up to 80%.
Well tolerated with mild to moderate treatment-emergent adverse events (TEAEs).
No negative impact on the visual cycle observed.
Interpretation:
Gildeuretinol shows promise in slowing disease progression in Stargardt disease without adverse effects on visual function.
Limitations:
TEASE-1's P value was not significant compared to TEASE-2.
Interim analysis in TEASE-3 involved a small sample size.
Conclusion:
The TEASE program supports the potential of gildeuretinol as a treatment for Stargardt disease, with ongoing studies expected to provide further insights.
